Evidence map›Paper›PMID 32157292›Full record

ArticleThe Journal of infectious diseases2021

Low Neuroactive Steroids Identifies a Biological Subtype of Depression in Adults with Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.

Shibani S Mukerji, Vikas Misra, David R Lorenz, Sukrutha Chettimada, Kiana Keller, Scott Letendre, Ronald J Ellis, Susan Morgello, Robert A Parker, Dana Gabuzda

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05570812 (In Vivo Targeting of Neuroactive Steroid and Immune Networks for Depression in People Living With HIV), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05570812 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

In Vivo Targeting of Neuroactive Steroid and Immune Networks for Depression in People Living With HIV

TypeinterventionalSponsorMassachusetts General HospitalRan2023 to 2028Enrolled120ConditionsMajor Depressive Disorder, Anxiety Depression, HIVArmsPlacebo, Pregnenolone
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shibani S MukerjiDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Vikas MisraDana-Farber Cancer Institute, Boston, Massachusetts, USA.
David R LorenzDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sukrutha ChettimadaDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kiana KellerMassachusetts General Hospital, Boston, Massachusetts, USA.
Scott LetendreUniversity of California, San Diego, School of Medicine, San Diego, California, USA.
Ronald J EllisUniversity of California, San Diego, School of Medicine, San Diego, California, USA.
Susan MorgelloIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Robert A ParkerMassachusetts General Hospital, Boston, Massachusetts, USA.
Dana GabuzdaDana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-4964-5083
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USUniversity of California San Diego · USIcahn School of Medicine at Mount Sinai · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
California NeuroAIDS Tissue NetworkU24MH100928 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACHIM, CRISTIAN L, MOORE, DAVID J · 2013 to 2023
$13.9M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
NNTC Data Coordinating CenterU24MH100925 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S, SHERMAN, SETH · 2013 to 2022
$9.5M
Systems Biology of Cognitive Decline in Older Adults with HIV InfectionR01MH097659 · NIMH · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2012 to 2016
$2.5M
Stress response networks in HIV infectionR01DA040391 · NIDA · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2015 to 2019
$2.2M
Neuroimmune mechanisms of depression in adults with HIV infectionR01MH110259 · NIMH · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2016 to 2020
$1.8M
Immune Activation, Cerebral Metabolic Activity and Depression in Treated HIV-InfectionK23MH115812 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI MUKERJI, SHIBANI SHARON · 2018 to 2022
$926k
Midcareer Investigator Award in Patient-Oriented NeuroAIDS ResearchK24MH097673 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LETENDRE, SCOTT L · 2013 to 2017
$917k
NIAID NIH HHS P30 AI060354NIDA NIH HHS R01 DA040391NIMH NIH HHS K23 MH115812NIMH NIH HHS K24 MH097673NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH097659NIMH NIH HHS R01 MH110259NIMH NIH HHS U24 MH100925NIMH NIH HHS U24 MH100928NIMH NIH HHS U24 MH100929NIMH NIH HHS U24 MH100930NIMH NIH HHS U24 MH100931
6 · The paper itself

Abstract

backgroundThe prevalence and mortality risk of depression in people with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy (ART) is higher than in the general population, yet biomarkers for therapeutic targeting are unknown. In the current study, we aimed to identify plasma metabolites associated with depressive symptoms in people with HIV receiving ART.

methodsThis is a prospective study of ART-treated HIV-infected adults with or without depressive symptoms assessed using longitudinal Beck Depression Inventory scores. Plasma metabolite profiling was performed in 2 independent cohorts (total n = 99) using liquid and gas chromatography and tandem mass spectrometry.

resultsParticipants with depressive symptoms had lower neuroactive steroids (dehydroepiandrosterone sulfate [DHEA-S], androstenediols, and pregnenolone sulfate) compared with those without depressive symptoms. The cortisol/DHEA-S ratio, an indicator of hypothalamic-pituitary-adrenal axis imbalance, was associated with depressive symptoms (P < .01) because of low DHEA-S levels, whereas cortisol was similar between groups. The odds of having depressive symptoms increased with higher cortisol/DHEA-S ratios (adjusted odds ratio, 2.5 per 1-unit increase in z score; 95% confidence interval, 1.3-4.7), independent of age and sex. The kynurenine-to-tryptophan ratio showed no significant associations.

conclusionsThese findings suggest that altered neuroactive steroid metabolism may contribute to the pathophysiological mechanisms of depression in ART-treated HIV-infected adults, representing a potential biological pathway for therapeutic targeting.

Indexed as

DepressionHIV InfectionsNeurosteroidsAdultDehydroepiandrosteroneHumansHydrocortisoneHypothalamo-Hypophyseal SystemPituitary-Adrenal SystemProspective StudiesDehydroepiandrosteroneHydrocortisoneNeurosteroidsacylcarnitinesdepressionDHEAHIVHPA axismetabolomicsneuroactive steroids

Identifiers

PMID32157292
PMCPMC8136979
OpenAlexW3011920098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.